Introduction
Basically, acute coronary syndrome (ACS) is caused by the partial or total occlusion of coronary arteries because of platelet activation and aggregation. Hence, one of the major components of ACS treatment is the inhibition of platelet activation and aggregation. Antiplatelet agents (APA) act by inhibiting the cyclooxygenase enzyme (aspirin) and P2Y 12 receptor. The main features of P2Y 12 receptor inhibitors are listed in Table 1 . New studies performed in recent years have led to the update of guidelines for the usage of APA in the treatment of ACSs. This paper aims to compare the European Society of Cardiology (ESC) (1, 2) and American Heart Association (ACCF/AHA) guidelines (3, 4) , by summarizing the key points, regarding the usage of oral APA in patients admitted to emergency departments due to ACS. APA strategies that should be chosen in ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI)/unstable angina (UA) pectoris cases were discussed under separate headings.
APA Treatment in STEMI
European Society of Cardiology (2) and AHA (4) guidelines on this subject were updated in 2012 and 2013, respectively. Both guidelines recommend the administration of aspirin as the first step (Class I), regardless of the treatment strategy chosen (i.e., fibrinolytic or percutaneous coronary intervention). Both guidelines also agree on the immediate initiation of dual antiplatelet therapy (a P2Y 12 inhibitor in addition to aspirin) (Class I). Drugs and dosages vary according to the chosen treatment strategy. Thus, the recommendations have been described separately with regard to treatment strategy. An initial aspirin dose of 150-500 mg and clopidogrel dose of 75 mg/day are recommended in patients for whom no reperfusion therapy is planned (2) . 
P2Y 12 Receptor Inhibitors
Both guidelines recommend the use of clopidogrel in patients with STEMI for whom fibrinolytic therapy is planned. However, prasugrel and ticagrelor should not be used in such patients because the use of these agents has not been studied yet as an adjunctive treatment in fibrinolysis (2, 4 
APA Treatment in UA/NSTEMI
Aspirin therapy significantly decreases the rates of mortality and reinfarction. Aspirin is recommended in the ESC and ACCF/AHA guidelines as it has been used for patients with STEMI (Class I). Aspirin should be administered as soon as possible following patient admission, if it is not contraindicated. A clopidogrel loading dose followed by maintenance doses should be administered to patients who cannot take aspirin due to hypersensitivity or gastrointestinal intolerance (Class IB). The usage of P2Y 12 receptor inhibitors together with aspirin provides an additive effect. Dual APA therapy is a Class IA recommendation in the ESC and ACCF/AHA guidelines. • Prasugrel is recommended after the patient is taken to the laboratory, and the coronary anatomy is seen if the patient was not given a P2Y 12 receptor inhibitor until he is taken to the laboratory (Class IB) Prasugrel is contraindicated in patients ≥75 years of age or <60 kg of weight or have a history of stroke/transient ischemic attack. Besides, prasugrel should not be used in patients with an unknown coronary anatomy (Class IIIB).
Aspirin
Cangrelor, another P2Y 12 receptor inhibitor, may be considered in patients who need to undergo percutaneous coronary intervention (Class IIbA). However, cangrelor is not approved by the European Medical Agency or the Federal Drug Administration. Thus, there is no specific recommendation for its usage.
Conclusion
The administration of aspirin as the first step is recommended for all patients with ACS. Since the usage of P2Y 12 receptor inhibitors together with aspirin provides an additive effect, immediate initiation of dual antiplatelet therapy is recommended, too. A combination of an initial aspirin dose of 150-500 mg and clopidogrel dose of 75 mg/day is recommended in STEMI patients for whom no reperfusion therapy is planned. Clopidogrel is recommended in patients with STEMI for whom fibrinolytic therapy is planned. If percutaneous coronary intervention is planned in a STEMI patient, prasugrel, and ticagrelor are preferred over clopidogrel. A clopidogrel loading dose followed by maintenance doses should be given to patients with UA/ NSTEMI who cannot take aspirin due to hypersensitivity or gastrointestinal intolerance. While choosing a P2Y 12 receptor inhibitor for a patient with UA/NSTEMI, clopidogrel should be used only if the patient cannot take prasugrel or ticagrelor. Prasugrel should not be used in patients with a history of stroke/transient ischemic attacks or ≥75 years of age or <60 kg of weight. It should also be emphasized that prasugrel can only be used after the coronary anatomy is seen.
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